Affomix to provide antibodies for Kalgene’s companion diagnostics program

BRANFORD, Conn.—Affomix Corp., a developer of automated,high-throughput monoclonal antibody selection technology, announced in lateDecember that it will use its Y2HExpress technology to select antibodies withpotential diagnostic and therapeutic utility in breast cancer for KalgenePharmaceuticals Inc., a private company focused on the development of oncologytherapeutics and companion diagnostics. Under the agreement, Affomix will useY2HExpress for the selection of single-chain antibodies for Kalgene, whoseportfolio of oncology products is at various stages in development, from assaydevelopment to advanced clinical trials. Financial terms of the serviceagreement were not disclosed, nor were the financial milestones related todiagnostic and therapeutic applications.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022